4-甲基-3-三氟甲基溴苄 | 261952-19-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-甲基-3-三氟甲基溴苄
• 英文名称: 4-methyl-3-trifluoromethyl benzyl bromide
• 英文别名: 4-(bromomethyl)-1-methyl-2-(trifluoromethyl)benzene；4-Methyl-3-(trifluoromethyl)benzyl bromide
• CAS: 261952-19-6
• 化学式: C₉H₈BrF₃
• 分子量: 253.062
• InChiKey: DEGVSFJBDJUTBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 海关编码：
  2903999090
• 包装等级：
  III
• 危险品运输编号：
  UN3261
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P270,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P363,P405,P501
• 危险性描述：
  H302,H314
• 储存条件：
  保存在惰性气体中，温度控制在2-8°C。

反应信息

• 作为反应物：
  描述：

  4-甲基-3-三氟甲基溴苄 在 sodium bromate 、 sodium hydrogensulfite 作用下， 以 水 、 乙酸乙酯 为溶剂， 反应 93.0h， 生成
  参考文献：
  名称：

  Polyfluorinated bis-styrylbenzenes as amyloid-β plaque binding ligands

  摘要：

  Detection of cerebral beta-amyloid (A beta) by targeted contrast agents remains of great interest to aid the in vivo diagnosis of Alzheimer's disease (AD). Bis-styrylbenzenes have been previously reported as potential A beta imaging agents. To further explore their potency as F-19 MRI contrast agents we synthetized several novel fluorinated bis-styrylbenzenes and studied their fluorescent properties and amyloid-beta binding characteristics. The compounds showed a high affinity for Ab plaques on murine and human brain sections. Interestingly, competitive binding experiments demonstrated that they bound to a different binding site than chrysamine G. Despite their high logP values, many bis-styrylbenzenes were able to enter the brain and label murine amyloid in vivo. Unfortunately initial post-mortem F-19 NMR studies showed that these compounds as yet do not warrant further MRI studies due to the reduction of the 19F signal in the environment of the brain. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2014.02.054

文献信息

• [EN] FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS À TITRE DE MODULATEURS DE S1P
  申请人：ABBVIE INC

  公开号：WO2017036978A1

  公开（公告）日：2017-03-09

  The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.

  这项发明涉及杂环化合物作为S1P调节剂，包括这种化合物的药物组合物，以及在治疗、缓解或预防由S1P受体介导的疾病或紊乱中的用途。
• [EN] PHENYL ALKANOIC ACID DERIVATIVES AS GPR AGONISTS<br/>[FR] DÉRIVÉS D'ACIDE PHÉNYLALCANOÏQUE EN TANT QU'AGONISTES DU RPG
  申请人：PIRAMAL ENTPR LTD

  公开号：WO2013128378A1

  公开（公告）日：2013-09-06

  The present invention relates to phenyl alkanoic acid derivatives (the compounds of Formula (I)); and their isotopic forms, stereoisomeric and tautomeric forms and mixtures thereof in all ratios, or pharmaceutically acceptable salts, pharmaceutically acceptable solvates, prodrugs, polymorphs, N-oxides, S-oxides or carboxylic acid isosteres thereof. The invention also relates to processes for the preparation of compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds of Formula (I). The said compounds and the pharmaceutical composition function as GPR (G-protein coupled receptor) agonists, particularly as GPR40 agonists, and are useful in the treatment of diseases or conditions mediated by GPR40. The present invention further relates to a method of treatment of diseases or conditions mediated by GPR40comprising administering to a subject in need thereof a therapeutically effective amount of the compounds of Formula (I).

  本发明涉及苯基烷酸衍生物（公式(I)的化合物）；及其同位素形式、立体异构体、互变异构体和所有比例的混合物，或其药物可接受的盐、药物可接受的溶剂化物、前药、多态性、N-氧化物、S-氧化物或羧酸的等排体。本发明还涉及制备公式(I)化合物的方法和包含一个或多个公式(I)化合物的药物组合物。所述化合物和药物组合物作为GPR（G蛋白偶联受体）激动剂，特别是作为GPR40激动剂，并且可用于治疗由GPR40介导的疾病或状况。本发明进一步涉及一种治疗由GPR40介导的疾病或状况的方法，包括向需要治疗的受试者施用治疗有效量的公式(I)化合物。
• INHIBITORS OF STEAROYL-COA DESATURASE
  申请人：Gillespie Paul

  公开号：US20090149466A1

  公开（公告）日：2009-06-11

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

  提供以下式(I)化合物： 以及药用可接受的盐，其中取代基如说明书中所披露。这些化合物以及包含它们的药物组合物可用于治疗诸如肥胖等疾病。
• [EN] NEW HETEROCYCLIC COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2020104494A1

  公开（公告）日：2020-05-28

  The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L, X, R1, R2, R3 and R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  这项发明提供了具有一般式(I)的新杂环化合物，其中A、B、L、X、R1、R2、R3和R4如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及使用这些化合物的方法。
• 一种含氟化合物及其制备方法和在制备抗肿 瘤药物中的应用
  申请人：山东师范大学

  公开号：CN110577563B

  公开（公告）日：2020-09-04

  本发明提供了一种含氟化合物及其制备方法和在制备抗肿瘤药物中的应用，该化合物具有式(I)所示结构：其中，‑CF3和R为苯环上的取代基，R选自氢、烷基、卤代烷基、烷氧基和卤素；以及，本发明还提供了式(I)化合物的药学上可接受的盐。本发明的化合物对胆管癌细胞和人胰腺癌细胞的增殖具有较好的抑制活性，本发明化合物对胆管癌细胞和人胰腺癌细胞增殖的具有很好的抑制活性，显著优于临床应用的氟尿嘧啶。